Atrial Fibrillation

Healio | Cardiology Today compiled a list of the top news from the 2023 American Heart Association Scientific Sessions.

PHILADELPHIA — A novel adhesive-based wearable cardioverter defibrillator was associated with high rates of patient compliance and low rates of adverse events, researchers reported at the American Heart Association Scientific Sessions.

Medtronic announced the U.S. launch of its left atrial appendage exclusion system for use during cardiac surgery in patients with preoperative atrial fibrillation.

Atrial fibrillation is a common arrhythmia that increases risk for stroke, HF and dementia. Although AF risk increases with age, it can also occur in young people with normal hearts, sometimes called “lone AF.”

PHILADELPHIA — Among patients hospitalized with atrial fibrillation discharged on a direct oral anticoagulant, more than 10% received an off-label dose, researchers reported at the American Heart Association Scientific Sessions.

PHILADELPHIA — In a phase 2b trial, abelacimab, a novel factor XI inhibitor, drastically reduced bleeding compared with rivaroxaban in patients with atrial fibrillation requiring stroke prevention.

PHILADELPHIA — In patients with subclinical atrial fibrillation, apixaban lowered risk for stroke but increased risk for bleeding compared with aspirin, according to the results of the ARTESIA trial.

Healio and Cardiology Today have aggregated news you may have missed from TCT 2023 in San Francisco.

SAN FRANCISCO — One-year data from the SWISS-APERO study show similar clinical outcomes and rates of patent left atrial appendages for patients undergoing LAA closure with either the Amulet or Watchman FLX devices, a speaker reported.

SAN FRANCISCO — Left atrial appendage occlusion at the time of transcatheter aortic valve replacement provides a noninferior treatment option to TAVR plus medical therapy in patients with severe aortic stenosis and atrial fibrillation.